GlassScriptPhysician profile
John M Lucas
NPI 1306998216
$2,943.70
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $981 · 2023: $763 · 2024: $30.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $639.04 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $526.49 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $293.11 | 2021-2024 | Farxiga |
| Amgen INC. | $224.42 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $202.20 | 2021-2024 | |
| Glaxosmithkline, LLC. | $188.72 | 2021-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.49 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $91.38 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $88.52 | 2021-2023 | Nexletol |
| Abbott Laboratories | $87.13 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $86.06 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $80.66 | 2021-2022 | |
| Amarin Pharma, INC. | $52.01 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.64 | 2022-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $34.47 | 2021-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.16 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $26.34 | 2023 | Evkeeza |
| Amneal Pharmaceuticals LLC | $22.09 | 2022 | |
| Sanofi Pasteur INC. | $19.80 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.32 | 2023 | |
| Exact Sciences Corporation | $17.71 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.81 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.97 | 2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $12.36 | 2021 | |
| Cequr Corporation | $10.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.